[Light and Shadow of Hyperuricemia - Neuroprotection, Comorbidities and Therapeutic Strategies]

Area of Science:

• Biochemistry
• Neurology
• Cardiology
• Nephrology

Background:

• Hyperuricemia, elevated uric acid levels, is primarily known for causing gout.
• It is also associated with significant comorbidities, including hypertension, kidney insufficiency, type 2 diabetes, myocardial infarction, and strokes.
• However, emerging evidence suggests a potential protective role of uric acid in certain inflammatory and degenerative neurological diseases.

Purpose of the Study:

• To explore the dual role of hyperuricemia, encompassing its detrimental effects and potential neuroprotective benefits.
• To review therapeutic strategies for managing hyperuricemia and its associated conditions.
• To discuss the role of interleukin-1 in gouty inflammation and its therapeutic implications.

Main Methods:

• Literature review of studies on hyperuricemia, gout, comorbidities, and neurological diseases.
• Analysis of the inflammatory pathways involved in gout, particularly interleukin-1.
• Evaluation of current and emerging therapeutic interventions for hyperuricemia.

Main Results:

• Hyperuricemia contributes to gout and various systemic comorbidities.
• Uric acid may exert positive effects on specific inflammatory and degenerative neurological conditions.
• Interleukin-1 plays a central role in gouty arthritis, with IL-1 antagonists showing therapeutic potential.
• Allopurinol, a first-line urate-lowering drug, demonstrates positive effects on associated comorbidities.

Conclusions:

• Hyperuricemia presents a complex clinical picture with both negative health impacts and potential neurological benefits.
• Targeting interleukin-1 offers a treatment option for refractory gout.
• Allopurinol is effective for lowering uric acid and managing related comorbidities, highlighting its importance in comprehensive patient care.